Biosero has announced collaboration and co-marketing agreement with Virscidian for medicinal chemistry applications in drug discovery. The partnership will allow the companies’ customers to more easily transfer data between software platforms so that analytical workflows can be automated. This way, more compounds can be tested and rapidly moved into follow up analysis without the need for human intervention (1).
Bruker has acquired a majority share in Biognosys. As part of the deal, Biognosys will access Bruker’s 4D proteomics timsTOF technology for its proteomics research; in turn, Biognosys will provide deep, peptide-level proteome insights for drug development – with the end goal of opening an advanced US proteomics CRO facility (2).
WatersCorp launched Glyphosate-V – a lateral flow strip test for glyphosate detection in a variety of different samples. The new technology can – according to Waters – identify low concentrations of glyphosate in 15 minutes, and requires little technical skill to obtain accurate results. Glyphosate-V could help food and agricultural operations identify and manage raw materials to regulatory compliance (3).
Vector BioPharma has entered a collaboration with Instituto de Biologia Experimental e Tecnológica to develop and implement analytical methods that enhance the safety and efficiency of gene delivery. The alliance aims to develop a high-throughput technique for full-to-empty capsid ratio quantification from both in-process and final purified samples (4).
Astrea Bioseparations has acquired advanced chromatography column manufacturer Delta Precision. The deal should expand Astrea’s range of separation apparatus and purification tools – complementing the company's existing portfolio of bioprocessing resins and reusable columns (5).
Georgia Hulme is Associate Editor at The Analytical Scientist